EGFR and familial pancreatic carcinoma: In a phase I/II in a series of seven patients with unresectable or metastatic pancreatic cancer, EGFR BATs infusions induced clinical responses with stable disease for 7.4 months, two complete remissions to chemotherapy given after EGFR BATs, and one complete response survivor at 60 months (18).